Skip to main content

Table 2 Univariate analyses of factor associated with local progression-free survival and overall survival for patients receiving abdominal re-irradiation using a hyperfractionated regimen

From: Hyperfractionated abdominal reirradiation for gastrointestinal malignancies

 

Local progression-free survival

Overall survival

Factor

Hazard ratio

95% Confidence interval

P-value

Hazard ratio

95% Confidence interval

P-value

Age at Reirradiation

  < 65

Reference

Reference

 

Reference

Reference

 

  ≥ 65

0.72

0.27–1.89

.501

0.60

0.24–1.48

.268

Gender

 Male

Reference

Reference

 

Reference

Reference

 

 Female

0.87

0.27–2.54

.806

0.58

0.20–1.46

.256

Primary Cancer

 Pancreatic Adeno

Reference

Reference

 

Reference

Reference

 

 Upper GI Adenoa

1.14

0.24–4.07

.856

1.36

0.20–4.60

.650

 Colon Adeno

1.12 × 10 –9*

5.67 × 10 − 55 -.35 *

.002 *

3.65

0.76–13.82

.098

 Hepatobiliaryb

0.78

0.17-2.72

.715

1.02

0.23–3.44

.976

 Otherc

0.66

0.03-3.66

.678

2.34

0.34–9.95

.334

Initial RT dose

  ≤ 45Gy

Reference

Reference

 

Reference

Reference

 

  > 45Gy

0.62

0.20–1.67

.361

1.09

0.41–2.69

.848

Interval between 1st and 2nd courses of RT

  < 1 year

Reference

Reference

 

Reference

Reference

 

  ≥ 1 year

1.19

0.12–3.28

.824

0.45

0.14–2.00

.261

Type of post-1st RT disease

 New Primary

Reference

Reference

 

Reference

Reference

 

 Recurrence

2.37

0.46–43.24

.351

0.50

0.16–2.22

.323

Reason for reirradiation

 Definitive

Reference

Reference

 

Reference

Reference

 

 Palliative

1.42

0.48–3.80

.510

3.38

1.24–9.03

.018

Reirradiation dose

      

  ≤ 30Gy

Reference

Reference

 

Reference

Reference

 

  > 30Gy

1.31

0.43–4.96

.650

1.10

0.44–3.13

.844

Reirradiation modality

 3DCRT

Reference

Reference

 

Reference

Reference

 

 IMRT

0.62

0.21–1.64

.342

0.84

0.31–2.06

.708

Concurrent chemo with reirradiation?

 No

Reference

Reference

 

Reference

Reference

 

 Yes

1.51

0.51–5.55

.473

0.75

0.30–2.13

.565

  1. *Only colon adenocarcinoma primary type was significantly associated with increased LPFS, but the sample size was small (n = 3), with two patients not progressing and a third patient not progressing for 10 years
  2. aUpper GI Adenocarcinoma = adenocarcinomas of the gastroesophageal junction (N = 1), stomach (N = 1) and duodenum (N = 2)
  3. bHepatobiliary Cancers = intrahepatic cholangiocarcinoma (N = 2), extrahepatic cholangiocarcinoma (N = 1) and hepatocellular carcinoma (N = 1)
  4. cOther = pancreatic neuroendocrine tumor (N = 1), Hodgkin Lymphoma treated with mantle and abdominal fields (N = 1)